Since its passage more than two years ago, the Jumpstart Our Business Startups (JOBS) Act, which was designed to decrease regulatory burdens for raising capital, has spurred more than 110 IPOs among biotechnology companies alone. These are companies working to find cures for cancer, cardiovascular disease, blood disorders, and infectious diseases, among other conditions. The Securities and Exchange Commission (SEC) is now in the process of finalizing another important provision of the law that could further encourage biotech capital formation and investment.